How Long Should You Continue Bisphosphonate Treatment for Osteoporosis? - Frankly Speaking EP 225Guest: Robert A. Baldor, MD, FAAFP
Music Credit: Richard Onorato

Join us for this episode as we review the recently published (Dec. 2020) cohort study in JAMA on using bisphosphonates to prevent hip fractures. We will review the utility of bisphosphonates after 5 years and how to discuss their risks and benefits with patients.

Episode References and Resources:

JAMA.2020;3(12):e2025190.doi:10.1001/jamanetworkopen.2020.25190
JAMA. 2018;319(24):2521-2531. doi:10.1001/jama.2018.7498
https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9

Begin

Already listened on another platform?

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 5/24/2021

Expiration Date: 5/24/2022

Topics

Learning Objectives

Describe the controversy surrounding the length of time to prescribe bisphosphonates for osteoporosis treatment.
Discuss a recent large cohort study specifically designed to understand the risks vs. benefits related to continuing or stopping bisphosphonate treatment beyond 5 years.
Engage patients with osteoporosis in shared decision making on the use of bisphosphonates in their treatment regimen

Faculty

Frank J. Domino, MD

Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA

Learn More

Robert A. Baldor, MD, FAAFP

Professor and Chairman, Dept of Family Medicine
UMass Medical School/Baystate

Learn More

Supported by

Not Applicable

Education Partner

Not Applicable